Secukinumab for the Treatment of Inflammatory Skin and Joint Disease

alkiviadis.1961 shared this article with you from Inoreader Secukinumab for the Treatment of Inflammatory Skin and Joint Disease Via Latest Results Abstract Psoriasis is a chronic inflammatory skin condition characterized by thick, erythematous, scaly plaques commonly found on the extensor surfaces, scalp, and trunk. While the etiology of this skin condition has not been fully elucidated, research has unequivocally shown that psoriasis represents a bona fide T cell-mediated disease that involves the skin, joints, and a myriad of other organs/tissues. The recent discovery of a set of pathogenic T cells that produce high levels of interleukin-17 in response to interleukin-23 led to a major paradigm shift in the pathogenic model for this condition resulting in numerous novel targeted immune therapies. The robust phase 3 clinical trial program for anti-interleukin-17A via secukinumab (sold under the brand Cosentyx®) for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis provides a solid foundation supporting the high clinical efficacy and safety of this medic ation in dermatology and rheumatology. While the exact roles of interleukin-17 in the development of inflammatory diseases is not entirely clear, ongoing research and clinical studies are expanding our knowledge base and leading to the development of new treatments that can improve clinical outcomes for patients affected by these conditions. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.